About a dozen years ago, Bellus Health was teetering on the brink of insolvency after a would-be treatment for Alzheimer’s disease turned out to be no better than placebo. Today, it is a rehabilitated enterprise with plans to contend with Merck, and it just took full control of its own destiny.

This week Bellus signed a deal to buy out its partners and acquire the full rights to BLU-5937, an in-development treatment for chronic cough. Much like a Merck drug called gefapixant, BLU-5937 targets a sensory receptor called P2X3, which plays a role in triggering coughing.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy